A radioimmunoassay has been established for the insulin-like growth factor-binding protein, isolated from a human transformed fibroblast cel l \ x=req-\ 
INTRODUCTION
Insulin-like growth factor-binding protein-6 (IGFBP-6) is a relatively recently discovered member of the IGFBP family. First identified as one of the IGFBPs in human cerebrospinal fluid (CSF), it has been puri¬ fied from that source (Roghani, Hossenlopp, Lepage et al. 1989) and from culture medium conditioned by two transformed human fibroblast cell-lines (Forbes, Ballard & Wallace, 1990; Martin, Willetts & Baxter, 1990) . It is also known to exist in ovarian follicular fluid, and cDNAs corresponding to the human and rat proteins have now been cloned from placental and ovarian cDNA libraries respectively (Shimasaki, Gao, Shimonaka & Ling, 1991) . The cDNA for human IGFBP-6 predicts a protein of 216 amino acids with a molecular mass of 22-8 kDa, high sequence homology with the other five known IGFBPs and a single Asnlinked glycosylation site (Shimasaki et al. 1991) . Competitive binding studies on the protein purified from various sources indicate a strong preferential affinity for insulin-like growth factor (IGF)-II over IGF-I (Roghani et al. 1989; Martin et al. 1990) .
It is becoming increasingly recognized that IGFBPs play important roles in regulating the bioavailability of the IGFs (Baxter, 1991) . In order to evaluate the contribution of IGFBP-6 to the IGF-binding capacity of serum and other body fluids, we have now devel¬ oped a radioimmunoassay (RIA) for human IGFBP-6, using the protein purified from fibroblast culture medium as antigen, standard and tracer.
MATERIALS AND METHODS

Proteins and peptides
Human IGFBP-6 was isolated from culture medium conditioned by the SV40-transformed human fibro¬ blast line AG2804; it appeared as a single band of approximately 34 kDa when detected by silver stain¬ ing after sodium dodecyl sulphate polyacrylamide gel electrophoresis (Martin et al. 1990 (Baxter, Martin & Wood, 1987) , ) and the acid-labile subunit of the 150 kDa serum IGF-binding complex (Baxter, Martin & Beniac, 1989) were puri¬ fied as previously described. Human IGF-I and IGF-II were purified from Cohn Fraction IV of human plasma (Baxter & De Mellow, 1986 
RESULTS
Under the assay conditions described, specific tracer binding was 25-8 ± 1-6% of total radioactivity (mean ± s.d., n = 12), non-specific binding (measured in the absence of primary antibody) was 2-5 ±0-4% and the concentration of standard which displaced 50% of bound tracer (ED50) was 0-47 ±009 ng/tube. The standard at 0025 ng IGFBP-6/tube gave a B/B0 value (i.e. ratio of radioligand bound to that bound in the absence of unlabelled ligand) of 0-947±0-022; this concentration was regarded as the theoretical minimum detectable dose. The within-assay impreci¬ sion for the means of duplicates, determined by analy¬ sis of variance of 20 duplicate pairs in each dose range, was 6-3% at 0-14 ng/tube, 4-8% at 0-53 ng/tube and 4-6% at 1-68 ng/tube. The between-assay imprecision calculated from three control samples run in duplicate in 12 assays was 21-7% at 012 ng/tube, 11-6% at 0-56 ng/tube and 7-3% at 1-65 ng/tube. As the specificity of IGF interference in the RIA was similar to that of IGF binding to IGFBP-6 (Martin et al. 1990 ), it seemed likely that occupancy of the IGF-binding site on IGFBP-6 affected its immunoreactivity. In an attempt to overcome this effect, increasing concentrations of pure human IGFBP-3 were added to incubation mixtures. In the absence of IGFs, IGFBP-3 had no effect on tracer binding (i.e. the B/B0 ratio) at up to 50 ng/tube, though a slight inhibition was seen at 100 ng/tube (Fig. 2) . The addition of increasing concentrations of IGF-II caused a dose-dependent decrease in B/B0, which could be fully reversed by adding IGFBP-3. As shown in Fig. 2a, 50 Various human body fluids (serum, amniotic fluid, CSF and follicular fluid) were tested in the IGFBP-6 RIA. Initially, each sample type was size fractionated on a Superóse 12 column and the immunoreactive IGFBP-6 in each fraction determined. Figure 4 illus¬ trates the immunoreactivity profiles, assayed in the presence and absence of 50 ng IGFBP-3. These stud¬ ies were performed seven times for serum, four times for CSF, and twice each for follicular fluid and amni¬ otic fluid. In serum samples assayed without IGFBP-3, two peaks were observed, a minor one in fractions 22-23 (corresponding to the 150 kDa complex) and a major one in fractions [26] [27] (corresponding exactly to the elution volume of IGFBP-6 purified from fibroblast-culture medium) (Martin et al. 1990 ). When assayed in the presence of IGFBP-3, the minor peak disappeared, while the major peak was unchanged. This is interpreted as an indication that IGFs in the 150 kDa serum IGFBP complex can dis¬ sociate during the course of the RIA, causing interfer¬ ence in the assay, and that IGFBP-3 added to the assay is able to overcome this interference.
Follicular fluid samples showed similar interference corresponding to the 150 kDa complex, which could be eliminated by assaying in the presence of IGFBP-3 (Fig. 4) . In these samples, some reduction in the apparent immunoreactivity of the major peak was also seen. In contrast to serum and follicular fluid, neither amniotic fluid nor CSF showed apparent im¬ munoreactivity of 150 kDa when analysed in this way. This is consistent with the absence of the acid-labile subunit, and thus of the high molecular weight IGFBP complex, in these fluids (Baxter, 1990) . Amni¬ otic fluid, but not CSF, showed a slight decrease in apparent immunoreactivity in the major peak when assayed in the presence of IGFBP-3 (Fig. 4) . Mean IGFBP-6 levels in the body fluids tested were 0-1-0-3 mg/1. The mean value for adult human serum, 0-22 mg/1, is comparable with levels of IGFBP-2 (Clemmons et al. 1991) and somewhat higher than IGFBP-1 (Yeoh & Baxter, 1988) but less than 5% of the IGFBP-3 level in adult human serum . Interestingly, CSF, the first described source of this protein (Roghani et 
